What Is Caplyta, and Why Does It Matter?
Caplyta (lumateperone) is a once‑daily atypical antipsychotic prescription medicine used to treat mental health conditions such as schizophrenia in adults. The FDA has updated Caplyta's label based on long‑term data that showed that it is safe and effective in preventing schizophrenia relapse over time. Previously, this medicine was used to treat schizophrenia by helping relieve active symptoms such as hallucinations, delusions, and disorganized thinking.
Schizophrenia is a long-term mental illness that can seriously disrupt a person's life. Symptoms differ from person to person, but confusion and changes in how patients see the world, manage emotions, or behave are common to all. One of the biggest challenges is relapse, when symptoms such as hallucinations or psychosis return. These episodes severely affect a patient's daily life, making it harder to work, maintain relationships, or live independently. In the U.S., about 2.8 million adults live with schizophrenia, and about 40% of them don't get enough treatment or care. On average, patients may have multiple relapses over time, which often leads to added medical costs and stress for families.
The exact way this drug works isn't fully understood, but it may help by balancing levels of certain brain chemicals (neurotransmitters) such as dopamine and serotonin that play a key role in schizophrenia. Caplyta does this by blocking the brain's serotonin receptors (5‑HT2A), linked to mood and thinking, while partly turning on brain's dopamine receptors (D2), associated with motivation and movement. Together, these actions can ease symptoms in people with schizophrenia.
First approved in 2019, Caplyta is also used to treat depressive episodes in patients with bipolar I or II disorder (alone or with lithium or valproate) and as an add‑on to antidepressants for major depressive disorder.
This update matters because Caplyta offers a therapeutic option for achieving steady long-term control by preventing schizophrenia relapse, reducing repeated hospital visits, and improving patients' quality of life.
Why Was It Approved?
The FDA's label update is based on long‑term results from a clinical study that showed that Caplyta was safe, well-tolerated, and effective at helping adults with schizophrenia stay well for longer.
In a phase 3 clinical study covering a 26-week treatment period, patients with schizophrenia who were treated with Caplyta had a 63% lower risk of relapse, compared with those treated with a placebo, and 84% of the patients remained relapse-free over six months. The treatment also significantly delayed the time to discontinuation for any reason, including relapse. The safety profile was consistent with that in previous studies, with no new safety concerns identified.
The most commonly reported side effect was headache. Across its approved uses, common side effects include sleepiness, dizziness, nausea, dry mouth, tiredness, and diarrhea.
Using antipsychotics in older adults with dementia-related psychosis raises the risk of stroke, which may lead to death. Also, antidepressants can raise the risk of suicidal thoughts and behaviors in children and young adults, especially within the first few months of treatment or when the dose is changed. Caplyta has not been shown to be safe or effective in children.
Other serious side effects linked to Caplyta include neuroleptic malignant syndrome, a life-threatening condition that can cause a high fever, sweating, confusion, stiff muscles, and changes in breathing, heart rate, and blood pressure; uncontrolled movements in the face, tongue, or other body parts (tardive dyskinesia); high blood sugar (hyperglycemia) and diabetes; increased levels of cholesterol and triglycerides in the blood; weight gain; low white blood cell counts; lightheadedness or fainting on standing up quickly from a sitting or lying position (orthostatic hypotension); and seizures (convulsions).
What Do I Need to Know?
This drug is taken by mouth once daily with or without food. Do not change the dose or stop taking Caplyta without first discussing it with your health care provider.
Caplyta can make you sleepy and can affect judgment, thinking, or coordination. Do not drive or use machines until you know how it affects you. It may cause dizziness or a drop in blood pressure when you stand up, which can increase the chance of falls. Seizures can happen, especially if you have a history of seizures or conditions that make seizures more likely.
During your treatment, avoid getting too hot or dehydrated. In hot weather, avoid strenuous exercise and limit sun exposure. Stay hydrated, wear light clothing, and whenever possible, remain indoors in a cool environment.
Before taking this drug, tell your health care provider if you have any medical conditions such as heart problems or a past stroke, blood pressure issues, diabetes or a family history of diabetes, high cholesterol or triglyceride levels, low white blood cell counts, or kidney or liver problems. You must not take Caplyta if you are allergic to it or any of its ingredients.
Caplyta works on brain chemicals such as serotonin. If it's taken with certain antidepressants that act via serotonin, it may increase the risk of side effects such as serotonin syndrome or low sodium levels (hyponatremia); your health care provider may monitor you more closely.
Your health care provider will also check your blood sugar, cholesterol, and/or triglyceride levels and blood pressure before starting and during treatment.
Be sure to tell your health care provider about all medicines you are taking – including prescription and over-the-counter medicines, health supplements, and herbal remedies – so they can adjust doses safely. This drug can interact with other medicines, which may lead to serious side effects. It may change how other medicines work, and in turn, those medicines can also affect how Caplyta works.
Caplyta may affect fertility in both women and men. If this is something you're worried about, speak with your health care provider. If you are pregnant, planning to become pregnant, or breastfeeding, talk with your health care provider. Use of this drug late in pregnancy (third trimester) may cause abnormal muscle movements or withdrawal symptoms in newborns, and small amounts pass into breast milk.
Watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings, and let your health care provider know about them right away.
Also contact your health care provider right away if you have a high fever, confusion, changes in your breathing, an increased heart rate and high blood pressure, stiff muscles, increased sweating, or if you have symptoms of high blood sugar such as excessive thirst or hunger, frequent urination, a fruity smell in your breath, extreme tiredness, or confusion.